The modified contract represents an additional commitment of up to $472 million to support the late-stage clinical development, including the expanded phase III study, of its mRNA vaccine candidate, mRNA-1273, against COVID-19.The collaboration is evaluating the combination of the latter’s stable prefusion form of the SARS-CoV2 recombinant spike protein with Dynavax’s advanced adjuvant CpG 101, which is present in the latter’s FDA-approved adult hepatitis B vaccine.